|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valastyan S and Weinberg RA: Tumor
metastasis: Molecular insights and evolving paradigms. Cell.
147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu L, Wang Z, Li XF, He X, Guan LL, Tuo
JL, Wang Y, Luo Y, Zhong HL, Qiu SP, et al: Screening and
identification of significant genes related to tumor metastasis and
PSMA in prostate cancer using microarray analysis. Oncol Rep.
30:1920–1928. 2013.PubMed/NCBI
|
|
4
|
Baek D, Villén J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang YL, Wu S, Jiang B, Yin FF, Zheng SS
and Hou SC: Role of microRNAs in prostate cancer pathogenesis. Clin
Genitourin Cancer. 13:261–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C,
et al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Z, He B, He J and Mao X: Upregulation
of miR-153 promotes cell proliferation via downregulation of the
PTEN tumor suppressor gene in human prostate cancer. Prostate.
73:596–604. 2013. View Article : Google Scholar
|
|
8
|
Lewis H, Lance R, Troyer D, Beydoun H,
Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, et al:
miR-888 is an expressed prostatic secretions-derived microRNA that
promotes prostate cell growth and migration. Cell Cycle.
13:227–239. 2014. View
Article : Google Scholar :
|
|
9
|
Verdoodt B, Neid M, Vogt M, Kuhn V,
Liffers ST, Palisaar RJ, Noldus J, Tannapfel A and
Mirmohammadsadegh A: Micro-RNA-205, a novel regulator of the
anti-apoptotic protein Bcl2, is downregulated in prostate cancer.
Int J Oncol. 43:307–314. 2013.PubMed/NCBI
|
|
10
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Josson S, Gururajan M, Sung SY, Hu P, Shao
C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, et al: Stromal
fibroblast-derived miR-409 promotes epithelial-to-mesenchymal
transition and prostate tumorigenesis. Oncogene. 34:2690–2699.
2015. View Article : Google Scholar
|
|
12
|
Rajendiran S, Parwani AV, Hare RJ,
Dasgupta S, Roby RK and Vishwanatha JK: MicroRNA-940 suppresses
prostate cancer migration and invasion by regulating MIEN1. Mol
Cancer. 13:2502014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun Q, Zhao X, Liu X, Wang Y, Huang J,
Jiang B, Chen Q and Yu J: miR-146a functions as a tumor suppressor
in prostate cancer by targeting Rac1. Prostate. 74:1613–1621. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dubovenko A, Serebryiskaya T, Nikolsky Y,
Nikolskaya T, Perlina A, JeBailey L, Bureeva S, Katta S, Srivastava
S, Dobi A, et al: Reconstitution of the ERG gene expression network
reveals new biomarkers and therapeutic targets in ERG positive
prostate tumors. J Cancer. 6:490–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiu J, Gao Z and Shima H: Growth of human
prostate cancer cells is significantly suppressed in vitro with
sodium butyrate through apoptosis. Oncol Rep. 27:160–167. 2012.
|
|
16
|
Shi C, Yu L, Yang F, Yan J and Zeng H: A
novel organoselenium compound induces cell cycle arrest and
apoptosis in prostate cancer cell lines. Biochem Biophys Res
Commun. 309:578–583. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Gong X, Chen J, Zhang J, Sun J and
Guo M: miR-340 inhibits glioblastoma cell proliferation by
suppressing CDK6, cyclin-D1 and cyclin-D2. Biochem Biophys Res
Commun. 460:670–677. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fernandez S, Risolino M, Mandia N, Talotta
F, Soini Y, Incoronato M, Condorelli G, Banfi S and Verde P:
miR-340 inhibits tumor cell proliferation and induces apoptosis by
targeting multiple negative regulators of p27 in non-small cell
lung cancer. Oncogene. 34:3240–3250. 2015. View Article : Google Scholar
|
|
19
|
Poenitzsch Strong AM, Setaluri V and
Spiegelman VS: MicroRNA-340 as a modulator of RAS-RAF-MAPK
signaling in melanoma. Arch Biochem Biophys. 563:118–24. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao
X, Zhang X, Cui L, Ye G, et al: Gastric juice miR-129 as a
potential biomarker for screening gastric cancer. Med Oncol.
30:3652013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Jia LS, Yuan W, Wu Z, Wang HB, Xu
T, Sun JC, Cheng KF and Shi JG: Low miR-34a and miR-192 are
associated with unfavorable prognosis in patients suffering from
osteosarcoma. Am J Transl Res. 7:111–119. 2015.PubMed/NCBI
|
|
22
|
Ma L, Reinhardt F, Pan E, Soutschek J,
Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW and Weinberg RA:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gordanpour A, Nam RK, Sugar L and Seth A:
MicroRNAs in prostate cancer: From biomarkers to molecularly-based
therapeutics. Prostate Cancer Prostatic Dis. 15:314–319. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bhatnagar N, Li X, Padi SK, Zhang Q, Tang
MS and Guo B: Downregulation of miR-205 and miR-31 confers
resistance to chemotherapy-induced apoptosis in prostate cancer
cells. Cell Death Dis. 1:e1052010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, Wan X, Chen H, Yang S, Liu Y, Mo W,
Meng D, Du W, Huang Y, Wu H, et al: Identification of miR-133b and
RB1CC1 as independent predictors for biochemical recurrence and
potential therapeutic targets for prostate cancer. Clin Cancer Res.
20:2312–2325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J,
Zhao JJ, Mao SS, Zhang GH, Xu XC and Zhang N: miR-340 inhibition of
breast cancer cell migration and invasion through targeting of
oncoprotein c-Met. Cancer. 117:2842–2852. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou X, Wei M and Wang W: MicroRNA-340
suppresses osteosarcoma tumor growth and metastasis by directly
targeting ROCK1. Biochem Biophys Res Commun. 437:653–658. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Honda R, Tanaka H and Yasuda H:
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
FEBS Lett. 420:25–27. 1997. View Article : Google Scholar
|
|
29
|
Montes de Oca Luna R, Wagner DS and Lozano
G: Rescue of early embryonic lethality in mdm2-deficient mice by
deletion of p53. Nature. 378:203–206. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Wu X, Lin J and Levine AJ: mdm-2
inhibits the G1 arrest and apoptosis functions of the p53 tumor
suppressor protein. Mol Cell Biol. 16:2445–2452. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rayburn E, Zhang R, He J and Wang H: MDM2
and human malignancies: Expression, clinical pathology, prognostic
markers, and implications for chemotherapy. Curr Cancer Drug
Targets. 5:27–41. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fortunato O, Boeri M, Moro M, Verri C,
Mensah M, Conte D, Caleca L, Roz L, Pastorino U and Sozzi G:
mir-660 is downregulated in lung cancer patients and its
replacement inhibits lung tumorigenesis by targeting MDM2-p53
interaction. Cell Death Dis. 5:e15642014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leite KR, Franco MF, Srougi M, Nesrallah
LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles
MI, Santana I, et al: Abnormal expression of MDM2 in prostate
carcinoma. Mod Pathol. 14:428–436. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Z, Li M, Wang H, Agrawal S and Zhang
R: Antisense therapy targeting MDM2 oncogene in prostate cancer:
Effects on proliferation, apoptosis, multiple gene expression, and
chemotherapy. Proc Natl Acad Sci USA. 100:11636–11641. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dar AA, Majid S, Rittsteuer C, de Semir D,
Bezrookove V, Tong S, Nosrati M, Sagebiel R, Miller JR III and
Kashani-Sabet M: The role of miR-18b in MDM2-p53 pathway signaling
and melanoma progression. J Natl Cancer Inst. 105:433–442. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tovar C, Rosinski J, Filipovic Z, Higgins
B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, et al:
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in
cancer: Implications for therapy. Proc Natl Acad Sci USA.
103:1888–1893. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vassilev LT, Vu BT, Graves B, Carvajal D,
Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et
al: In vivo activation of the p53 pathway by small-molecule
antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Allen JG, Bourbeau MP, Wohlhieter GE,
Bartberger MD, Michelsen K, Hungate R, Gadwood RC, Gaston RD, Evans
B, Mann LW, et al: Discovery and optimization of
chromenotriazolopyrimidines as potent inhibitors of the mouse
double minute 2-tumor protein 53 protein-protein interaction. J Med
Chem. 52:7044–7053. 2009. View Article : Google Scholar : PubMed/NCBI
|
